This module uses fundamental data of Nanobac Pharmaceuticals to approximate its Piotroski F score. Nanobac Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Nanobac Pharmaceuticals Incorporated. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Nanobac Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Nanobac Pharmaceuticals Altman Z Score, Nanobac Pharmaceuticals Correlation, Nanobac Pharmaceuticals Valuation, as well as analyze Nanobac Pharmaceuticals Alpha and Beta and Nanobac Pharmaceuticals Hype Analysis.
Nanobac
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Earnings Yield
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Capital Expenditures
Total Cash From Financing Activities
Change To Liabilities
Change To Inventory
Total Cashflows From Investing Activities
Change To Account Receivables
Other Cashflows From Investing Activities
Sale Purchase Of Stock
Change In Cash
Net Borrowings
Other Cashflows From Financing Activities
Depreciation
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Change To Netincome
Total Assets
Other Current Liab
Total Current Liabilities
Accounts Payable
Total Liab
Common Stock
Cash
Other Assets
Good Will
Inventory
Intangible Assets
Property Plant Equipment
Total Stockholder Equity
Other Liab
Net Tangible Assets
Retained Earnings
Net Receivables
Other Stockholder Equity
Short Long Term Debt
Total Current Assets
Short Term Debt
Selling General Administrative
Total Revenue
Gross Profit
Cost Of Revenue
Research Development
Operating Income
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Other Operating Expenses
Probability Of Bankruptcy
As of 12/02/2024, Total Debt To Capitalization is likely to grow to 1.77, while Short and Long Term Debt is likely to drop slightly above 3.4 M. At this time, Nanobac Pharmaceuticals' ROE is relatively stable compared to the past year.
At this time, it appears that Nanobac Pharmaceuticals' Piotroski F Score is Very Weak. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Nanobac Pharmaceuticals is to make sure Nanobac is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Nanobac Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Nanobac Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Nanobac Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Nanobac Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.006215)
At this time, Nanobac Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year.
About Nanobac Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanobac Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanobac Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanobac Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.